Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

a lung cancer drug. On Nov. 7, AstraZeneca stock crashed more than 7% after a report indicated dozens of employees could have been involved, Reuters reported. "As a matter of policy, we do not comment ...

It’s possible to catch a cold or get the flu at any time of year. But the chances of becoming sick increase during cold and ...

AstraZeneca has put a £450m investment in Britain on hold ... so that some patients could be eligible for insurance coverage ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

As the company restructures, it will pivot to selling genetic tests to consumers and using that data for research. Also: medicinal and tech advancements in cancer care; research monkeys roundup.

AstraZeneca and Daiichi Sankyo withdrew their filing for datopotamab deruxtecan (Dato-DXd) in nonsquamous non-small cell lung ...

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...

AstraZeneca now expects 2024 revenue and core earnings per share to grow by a high-teens percentage, from a previous forecast ...

AstraZeneca's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...